Scarica l'app Stockscreener
19.81
0.22%
-0.0523
Precedente Chiudi:
$19.86
Aprire:
$19.79
Volume 24 ore:
2.42M
Relative Volume:
0.44
Capitalizzazione di mercato:
$9.89B
Reddito:
$4.72B
Utile/perdita netta:
$-232.00M
Rapporto P/E:
-42.48
EPS:
-0.4663
Flusso di cassa netto:
$284.00M
1 W Prestazione:
-8.76%
1M Prestazione:
-16.32%
6M Prestazione:
-7.36%
1 anno Prestazione:
+53.38%
Intervallo 1D:
$19.72
$20.28
Intervallo di 1 settimana:
$19.72
$22.17
Portata 52W:
$12.40
$27.72
Elanco Animal Health Inc Stock (ELAN) Company Profile
Nome
Elanco Animal Health Inc
Settore
Telefono
877-352-6261
Indirizzo
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
19.80 | 9.92B | 4.72B | -232.00M | 284.00M | -0.4663 |
TAK
Takeda Pharmaceutical Co Adr
|
16.65 | 52.48B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.13 | 39.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.17 | 39.93B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.59 | 31.12B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
564.87 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Citigroup | Buy |
| 2026-01-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-21 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Aggiornamento | Argus | Hold → Buy |
| 2025-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Iniziato | UBS | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Market Perform |
| 2024-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Aggiornamento | Stifel | Hold → Buy |
| 2023-12-19 | Iniziato | Jefferies | Buy |
| 2023-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-04-20 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Downgrade | Goldman | Buy → Sell |
| 2022-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-28 | Downgrade | Stifel | Buy → Hold |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-06-15 | Aggiornamento | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Iniziato | Stifel | Buy |
| 2021-03-22 | Downgrade | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Downgrade | Argus | Buy → Hold |
| 2020-11-09 | Downgrade | Barclays | Overweight → Underweight |
| 2020-08-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Ripresa | Credit Suisse | Neutral |
| 2020-08-04 | Ripresa | Goldman | Buy |
| 2020-07-27 | Downgrade | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Iniziato | Barclays | Overweight |
| 2019-08-26 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Neutral |
| 2019-03-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Iniziato | William Blair | Mkt Perform |
| 2019-01-23 | Iniziato | UBS | Sell |
| 2019-01-15 | Iniziato | Argus | Buy |
| 2018-10-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Elanco Animal Health Inc Borsa (ELAN) Ultime notizie
Elanco (ELAN) Launches New Canine Allergy Treatment Befrena - GuruFocus
Elanco Animal Health’s SWOT analysis: stock outlook amid growth targets - Investing.com
Elanco launches canine dermatitis treatment Befrena in U.S. By Investing.com - Investing.com Canada
Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market - PR Newswire
Elanco Q1 2026 Earnings: Revenue $1.37B, EPS $0.40, Guidance RaisedNews and Statistics - IndexBox
5 Insightful Analyst Questions From Elanco’s Q1 Earnings Call - Yahoo Finance
Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- What GF Score of 70 Tells Investors - GuruFocus
Elanco finalizes acquisition of AHV International - Feed Strategy
Morgan Stanley Maintains Elanco Animal Health(ELAN.US) With Hold Rating, Raises Target Price to $23 - Moomoo
Elanco to Participate in Investor Conferences - Intellectia AI
Elanco to Participate in Upcoming Investor Conferences - GuruFocus
Dodge & Cox holds 13.9% of Elanco (NYSE: ELAN) in 13G/A amendment - Stock Titan
How to listen in as Elanco execs talk to investors in May and June - Stock Titan
Elanco reaches $9.3M settlement with consumers over antitrust allegations involving flea and tick products - Indianapolis Business Journal
Elanco to pay $6.75M to settle antitrust allegations involving flea and tick products - Inside INdiana Business
Primecap Management reports 9.22% stake in Elanco (ELAN) - Stock Titan
Elanco On Hook For Bulk Of $9M Flea & Tick Meds Deal - Law360
Earnings call transcript: Elanco Q1 2026 beats forecasts with strong growth - Investing.com Canada
Pet Wellness Products Market Touching New Development Level | Zoetis, Elanco, Virbac - openPR.com
Elanco Animal Health Inc (ELAN) Shares Fall 8.2% -- GF Value Says Still Overvalued - GuruFocus
Elanco (ELAN) Q1 earnings: What to expect - MSN
Elanco Animal Health Q1 Earnings Call Highlights - MarketBeat
Q1 2026 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Q3 2025 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Elanco Animal Health Inc Investor Day Transcript - GuruFocus
ELAN SEC FilingsElanco Animal Health 10-K, 10-Q, 8-K Forms - Stock Titan
Elanco (ELAN) shares climb after strong quarterly results and higher full-year outlook - msn.com
MSN Money - MSN
Elanco Animal Health Price Target Raised to $31.00/Share From $30.00 by Citigroup - Moomoo
Elanco Animal Health 1Q Adj EPS 40c >ELAN - Moomoo
ELAN Maintained by Citigroup -- Price Target Raised to $31.00 - GuruFocus
ELAN Maintained by JP Morgan -- Price Target Raised to $30 - GuruFocus
Elanco Earnings Call Highlights Innovation-Led Growth - The Globe and Mail
Elanco Animal Health Is Maintained at Overweight by JP Morgan - Moomoo
Elanco Animal Health Boosts Full Year Forecast - marketscreener.com
Elanco Animal Health Is Maintained at Buy by Citigroup - Moomoo
Elanco Animal Health (ELAN) Is Up 20.1% After Raising 2026 Guidance On Innovation-Led Growth - Yahoo Finance
Elanco Animal Health Incorporated (NYSE:ELAN) Q1 2026 Earnings Call Transcript - Insider Monkey
Citi Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Jefferies raises Elanco Animal Health stock price target to $30 By Investing.com - Investing.com Canada
Stifel reiterates Buy on Elanco Animal Health stock, $32 target By Investing.com - Investing.com Canada
Elanco Animal Health (NYSE:ELAN) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
ELAN Q1 Deep Dive: Innovation Products and Margin Expansion Steer Strong Start - The Globe and Mail
Elanco jumps after Q1 beat and higher 2026 outlook - Quiver Quantitative
Elanco Animal Health CEO reveals efforts to stop screwworm outbreak - Yahoo Finance
BofA raises Elanco Animal Health stock price target on strong Q1 - Investing.com Canada
Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum - Benzinga
Elanco Animal Health 2026 Q1 10-Q: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Elanco Animal Health Q1 2026 Earnings Call Transcript - MarketBeat
Elanco’s stock climbs after company posts strong 1st quarter results - Indianapolis Business Journal
Elanco Is Finally Realizing Its Transformation From Caterpillar to Butterfly - Morningstar
Elanco Animal Health Inc Azioni (ELAN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):